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Abstract
HMG 1 is a nonhistone chromosomal protein that binds preferentially to some types of
globally modified DNA. HMG I has been implicated in the cellular response to the

anti~cer

agent cisplatin, functioning to block excision repair of specific distorted platinated DNA lesions
and resulting in enhanced cytotox..icity. We have investigated whether other DNA-binding agents
also produce lesions that are recognized by HMG I. Specifically, we used polyacrylamide gel
shift assays to monitor the potential HMG I binding of diepoxybutane interstrand cross-links,
which have been suggested to induce DNA bending. We isolated the native protein from chicken
erythrocytes and expressed engineered HMG domain proteins in E. coli. Preliminary studies
support weak. binding of the HMG A domain protein to the cross-linked DNA oligomer.
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Introduction
Goals
Diepoxybutane (DEB) and other epoxides have long been characterized as carcinogens
(Ehrenberg & Hussain, 1983). While the mechanism by which these compounds exert their
biological activity is unclear, recent studies suggest that the cellular protein HMO 1 plays a role
in recognizing some DNA cross-links. The interaction of HMG 1 with cisplatinated DNA has
been well studied (Jamieson, 1999) but little else is known about HMO 1's ability to recognize
DNA cross-linked with other agents, including epoxides, and about how this information might
be linked to the chemotherapeutic effects of cisplatin and other antitumor agents. Through our
study, we have attempted to isolate the HMG 1 protein from chicken erythrocytes in a
continuation of the work done by Tiffany Frazar (2001) to learn more about its ability to
recognize cross-linked DNA. We hoped to use non-denaturing polyacrylamide gel
electrophoresis (p AO E) as a way of isolating HMG 1 protein most effectively from other nuclear
proteins. Additionally, we have used native gel shift assays to study the two functional domains
of HMO I separately and to better understand the interaction between the peptides and various
DNA oligomers. We hoped to find a correlation between the effectiveness of an antitumor agent
and the ability of HMG 1 to recognize cross-links resulting from such agents. We also wished to
better understand the factors that determine the carcinogenicity versus chemotherapeutic
potential of cross-linking compounds in terms of their interactions with HMO1 to aid in future
drug design.
Epoxides
In mammals, hydrocarbons are converted to water-soluble epoxide derivatives by
10

cytochrome P-450 during the detoxification process in the liver (Radski & Williams, 1998).
These epoxides are then excreted (Dipple, 1994). The problem with this system of detoxification
by conversion to epoxides is that epoxides can alkylate DNA and therefore act as carcinogens by
affecting the structure of DNA. Epoxides are also used as pesticides and as sterilizing agents for
food and medical equipment and occur naturally as mold contaminants (Millard & White, 1993).
Diepoxybutane and diepoxyoctane are two epoxides of interest, particularly in light of their
frequent use in industry. Diepoxybutane (DEB) (Figure 1) is a bifunctional alkylator that has
been linked to lymphatic and hematopoietic cancers in people exposed to butadiene (the
compound that is converted to DEB in the liver) in industrial settings (Divine, 1990; Mehlman &
Legator, 1991; Divine et aI., 1993). Its increased carcinogenicity relative to monoalkylating
agents may be due to its ability to form DNA interstrand cross-links (Loveless & Ross, 1950;
Haddow, 1958). One explanation for the carcinogenicity of butadiene may be that the interstrand
cross-links, formed when butadiene is converted to DEB, are largely undetected by the
nucleotide excision pathway and therefore persist in the cell. DEB can cause chromosomal
deletions and exchanges (Ehrenberg & Hussain, 1983). Repair inhibition leads to increased
problems for the cell as mutations may lead an increased cellular half-life. An increased half-life
may be responsible for the increase in mutagenicity of butadiene (Carmicbal et aI., 2000).
Genetic differences in the enzymes that cause the metabolic activity of butadiene and differences
in tbe enzymes responsible for repair of damaged DNA (Wieneke & Kelsey, 1993) may cause
different people to have different sensitivities to DEB. Researchers believe that interstrand cross
links are highly cytotoxic whereas intrastrand cross-links are mutagenic (Carmichal et at., 2000).

11
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Figure 1. The structure of diepoxybutane (DEB).
Interestingly, while DEB may be carcinogenic, similar cross-linking agents have been
used quite effectively as anti-tumor agents. The nitrogen mustards and cisplatin also cross-link
DNA and have been used to treat various forms of cancer for many years (reviewed by Radski &
Williams, 1998). The prodrug treosulfan, used to treat advanced ovarian cancer, is converted in
vivo to DEB and leads to interstrand cross-linking, which is suspected to be related to the

biologically relevant events leading to its antitumor effect (Hartley et aI., 1999). It appears that
DEB and the nitrogen mustards cross-link preferentially to the same sequence of DNA (Millard
& White, 1993). There is currently much interest in what causes the differential activity of the

chemotherapeutic agent and the carcinogen. It is possible that the biological effects of such anti
tumor agents as well as that of carcinogens may be due to the ability of certain cellular proteins
to recognize distorted DNA (MeA 'Nulty & Lippard, 1995). HMG I is an example of such a

protein.
Like the nitrogen mustards, which were among the earliest anti-tumor agents
characterized, DEB was found to act as a cross-linking agent over forty years ago. DEB forms
linkages between deoxyguanosines at the N7 position (Brooks & Lawley, 1961; Alexander et aI.,
1959). (Figure 2) Cross-linkers of five or fewer atoms were thought to form interstrand cross
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linkages at 5'-GC sequence with the minimal N7-to-N7 distance in B DNA (Brooks & Lawley,
1961 and 1967). However, recent evidence indicates that the five atom nitrogen mustards prefer
cross-linking distal deoxyguanosine (dG) at the 5'·GNC sequence in short oligomers and longer
restriction fragments (Ojwang et al., 1989; Millard et al., 1990; Rink et a1., 1995; Millard et aI.,
1996). Bifunctional alkylators must span 8

A to link dG in static B DNA at 5'-GC, and this

requirement would preclude agents of less than seven carbon atoms in length from acting as
crosslinkers. However. experimental evidence suggests that such cross-linking does occur (Van
Duuren and Goldschmidt 1966). Therefore, considerable distortion of the DNA must result
from the N7-to-N7 cross-Links at the 5'-GNC sequence on opposite strands (Millard et a1., 1990;
Rink et al., 1995; Millard & White 1993; Hopkins et aI., 1991). The ability of the nitrogen

mustards to span 8.9

A provides evidence for the conformational flexibility of DNA, which is

necessary to permit DEB to cross-link such a long distance.
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Figure 2. A DEB-cross-link. DEB fonns covalent bonds with guanines at
the N7 position to form interstrand cross-links.
While 5'-GNC is the principal target of DEB in short oligomers, 5'-GNNC is the
secondary site with -50% of the frequency of 5'-GNC when both are in a single duplex (Millard
& White, 1993; Yunes et aI., 1996). The fact that DEB and the nitrogen mustards target the
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same DNA sequence suggests that the sequence preference cannot account for differing selective
toxicities of these compounds (Millard & Wbite, 1993). Many studies have been done in an
attempt to understand the role of nitrogen mustards as chemotherapeutic agents. However, less
is known about the structural alterations upon DEB cross-linking, and little is understood about
the difference in cellular activity of DEB and chemotherapeutic agents.
Cisplatin
Cis-Diamminedicbloroplatinum (I I) (cisplatin) is another important chemotherapeutic
agent. It is able to bind to and modify the structure of DNA by fonning adducts recognized by
cellular proteins such as HMG 1 (McA'Nulty & Lippard, 1995). Cisplatin results in 1,2
intrastrand cross-links at d(GpG) and d(ApG) in duplex DNA (Eastman, 1987; Fichtinger
Schepman et at., 1985) and also in 1,3-intrastrand cross-links (pil & Lippard, 1992). The
resulting l,2-intrastrand cross-links bend the helix by 34° in the direction of the major groove
and unwind it by 13° (Fichtinger-Schepman et aI., 1985; Eastman, 1987) while the 1,3
intrastrand cross-links at d(GpTpG) bend the helix a similar amount but unwind it by 23° (Bellon
et at., 1991; Bellon & Lippard, 1990). Cisplatin, Iike the nitrogen mustards, targets the N7 of
guanine residues in DNA (Jamieson & Lippard, 1999). It also fonns interstrand cross-links
between dG residues at the 5'-GC sequence in free DNA (Hopkins et al., 1991; Lemaire et at.,
1991). While these interstrand products may be only a minor component of DNA lesions caused
by cisplatin (.. . .5-10% ofadducts), the relative contribution of the various intra- and interstrand
cross-linked products to cytotoxicity is unclear (Malinge & Leng, 1999). Cisplatin adducts are
recognized by proteins including those involved in replication, transcription, repair and apoptosis
(Pil & Lippard, 1992). The trans isomer of cisplatin is also capable of binding DNA and blocking
replication but does not have cisplatin's chemotherapeutic abilities (Pil & Lippard, 1992). The
14

trans isomer is thought to form interstrand and intrastrand cross-links, which are repaired more

efficiently than cross-links of cisplatin (Kasparkova et a1., 2000). Pit and Lippard (1992)
speculated that cisplatin's effectiveness as an antitumor agent may be due to a specifically
identifiable motif or shape of the DNA, which triggers a cellular response leading to cell death
and destruction of the tumor.

HMG proteins
Most DNA found in the cell is not found in a free state but rather is complexed with
proteins. It is these complexes that become chromosomes. The major proteins involved in
complex.ing DNA to fonn chromatin are the histone proteins. The non-histone chromosomal
proteins also have an important role and can be broken into two categories based on
trichloroacetic acid precipitation and the movement oftbese proteins via PAGE (Goodwin et aI.,
1973; Goodwin & Johns, 1973). These groups are the low-mobility and high mobility group
(HMG) proteins. The four major proteins of the HMG fraction include HMG1, HMG2, HMG 14
and HMG17 (Goodwin et aI., 1977; Sanders, 1977). HMGl is very similar in characteristics to
HMG2 and is about 28kDa (Toney et aI., 1989). Both HMG 1 and HMG2 have been found to
bind to DNA (Shooter et aI., 1974; Goodwin et aI., 1975; Yu et aI., 1977) and to histone HI
(Smerdon & Isenberg, 1976).
The exact role of HMG 1 and many of the other HMG proteins is not known. However,
during a study done in HMG I knockout mice, the HMG 1 knockout mice were born alive but
died within 24 hours of hypoglycemia This suggests that while HMGl may not be critical for
overall organization of chromatin, it has an important role in controlling specific transcription
factors (Calogero et aI., 1999). While the HMG domain sequence is not highly conserved,
research also suggests that there is too little sequence specificity between HMG 1 and HMG2
15
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L-shaped fold of the a-helical domain is highly conserved (Hardman et aI., 1995; Werner et a1.,
1995; Love et a1., 1995; Landsman & Bustin, 1993; Grosschedl et aI., 1994). The concave
structure of the protein is believed to be where the protein makes contact with the DNA (Werner
et aI., 1995; Love et at, 1994; Ohndorfetal., 1999). HMGl actually conmins two HMG

domains, HMG domain A and HMG domain B. Other proteins, such as SRY, the human testis
determining protein, and UBF (upstream binding factor), which is an RNA polymerase
transcription factor essential for efficient transcription of rRNA genes, also contain the HMG
domain (reviewed by Thomas & Travers, 2001). HMGl 's A and B domain are both basic and are
followed by the highly acidic C-terminal domain. The C-terminal domain consists of a run of 30
glutamate or aspartate residues (Kaplan & Duncan, 1988; Walker et aI., 1978). The C-terminal
tail, which flanks the B domain but not the A domain, seems to be important for stimulation of
DNA ligation by the HMG domain (~tros & Jovin, 2000). While the A and the B domain share
the same basic characteristics, the A and B domain ofHMG1I2 differ in their relative disposition
of the helices I and II and in the trajectory of the helix I-II loop (Hardman et a1., 1995).
HMGl binds to the minor groove of DNA independent of the sequence of the DNA
(Bustin & Reeves, 1996). It induces bends in the linear DNA substrate and supercoiling in the
constrained molecule of DNA (Bustin et aI., 1990; Stros et a1., 1994). HMG 1 is also thought to
bind preferentially to DNA containing sharp bends and twists characteristic of those resulting
from cross-linking of DNA by cisplatin (Locker et aI., 1995). Binding of HMG I in the minor
groove ofB DNA results in widening of the groove and causes bending of the helix (Werner et
al., 1995). Dunham and Lippard (1997) suggest that the presence of a single platinum lesion,
resulting from cisplatin intrastrand cross-lioking, increases the affInity of HMGl domain A for a
15-bp duplex by approximately three orders of magnitude and this work was confmned by
17

further studies (Cohen et a1., 2(00). Dunham and Lippard further suggest that the flanking
sequence affects the interaction of either isolated domain or full length HMG 1 (Dunham, 1997)
with the duplex with the base pair that is 3' to the lesion having the dominant effect
A single HMG domain is sufficient for recognizing cisplatin-modified DNA. The
distortions induced by the platinum complex, which may be recognizable by HMG I, include
destaeking of the platinum modified bases (Sherman et aI., 1985), unwinding of the duplex
(Bellon et al., 1991), bending of the helix toward the major groove (Chow et aI., 1995; Bellon &
Lippard, 1990) and widening/shallowing of the minor groove (T akahara et aI., 1996). This
wider, shallower minor groove is characteristic of A-type duplex oligomer encountered in RNA
and DNAJRNA hybrid helices active in transcription, replication and reverse transcription
(Salazar et al., 1993a; Salazar et a1., 1993b; Salazar et a!., J 994; Fedoroff et al., 1993). The
distortion of the DNA may more closely resemble the naturally occurring binding site of HMG 1
than the double helix (Cbow et al., 1995). This provides further evidence that HMG1 may be
involved in transcription.
Interestingly, treatment with cisplatin alters the cellular levels of HMG 1. Several
hundred thousand copies of the HMGl proteins may be found in one nucleus (Goodwin & Johns,
1973). The protein is also found in the cytoplasm. HMG 1 is found in all cells at an average of
one molecule per 10 to 15 nucleosomes (Bustin & Reeves, 1996; Bustin, 1999). Nonnally, cells
contain HMG proteins both in the nucleus and in cytoplasmic compartments (Chao et al., 1996).
However, cytoplasmic staining for detection of HMG 1/2 is less pronounced in cells exposed to
higher cisplatin concentrations. The ratio of nuclear to cytosolic HMG 1/2 increases following
treatment with cisplatin. This suggests that HMG I and 2 migrate from the cytosol to the nucleus
to bind cis-Pt-DNA adducts in the genomic DNA following treatment with cisplatin (Chao et a1.,
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1996). HMG 1 also appears to be up-regulated when human MCF-7 breast cancer cells are
treated with estrogen prior to treatment wlth HMG 1. Perhaps estrogen plays a role in sensitizing
cells to cisplatin. It appears to increase the HMGl mRNA levels by 1.5 to 2.5 fold (Chau et aI.,
1998). Over time, some cells can also become resistant to cisplatin, and this is associated with
an improvement in the repair of interstrand cross-links (Zhen et aI., 1992; Johnson et aI., 1994).

Project Design
The goal of our study was to isolate HMG 1 and to investigate its binding with diepoxide
cross-linked DNA to understand more about how HMG 1 recognizes modified DNA and learn
more about other important characteristics of DNA adducts for future drug design. We also wish
to study the A and B domains of HMG 1 separately to learn more about their binding interactions
with modified DNA.
To achieve our goals, we first isolated HMG 1 from chicken erythrocytes through NaCl
extraction. We attempted further purification from HMG2, a protein of the HMG family with
very similar characteristics, via native gel purification in an attempt to get pure protein without
the need for HPLC or column chromatography. We also attempted to isolate the HMG A and B
domain from expression vectors obtained from the Lippard lab (Department of Chemistry,
Massachusetts Institute of Technology). The protein was expressed in E. coli and purified via
column chromatography. This was done for both the A and B domain independently.
Once the HMG A domain was obtained, we studied the interaction of the domain with
DNA. The binding studies for the HMG A domain protein involved the use of a DNA fragment
of 30 bp. The duplexes were 5'-end-radiolabeled before being treated with the diepoxides. The
cross-linked DNA was gel purified via denaturing PAGE and renatured. Native gel shift assays
were used to determine whether the HMO domains were bound to the labeled DNA. This
19

allowed us to learn more about the recognition by HMG 1 of modified DNA. Using the domain
proteins, smal1er synthetic oligoroers could be used for the binding studies. These oligomers
were easier to renature. In addition, the use of the domain proteins may be preferable because
their expression appears to be less lethal to E. coli.
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Materials and Methods
Isolation of HMGl from chicken erythrocytes.
Preparation of Nuclear Extract. Two 5-rnL aliquots of frozen chicken erythrocytes
were thawed by adding 5 mL of sterile cell lysis buffer (0.01 M Tris [pH 7.2],0.15 M
NaCI, 0.5 roM PMSF) repeatedly until the sample became dark red. The cells were
centrifuged at 4200 rpm (2000xg) for 10 minutes to pack the nuclei, and the supernatant
was removed by vacuum filtration. The cells were then washed with cell lysis buffer and

with decreasing amounts of Igepal starting with 1 mL 10% Igepal in 50 mL of buffer and
decreasing to 0.2 mL 10% Igepal in 50 mL of buffer for the fourth wash. The samples
were spun at 1500xg for 10 minutes with each wash. The samples were spun one last
time at 1500xg for 10 minutes following the [mal wash.
NaO Extraction. 2 mL ofTris (1.0 mM [pH 7.5]) was added to the pellet followed by
the addition of 4 M NaCI solution (4M NaCl, 1 roM Tris [pH 7.5]) to a final
concentration of 0.35 M NaCI. This addition was done slowly by dialing down a pipette
over the course of 30 minutes at 4° C. The samples were centrifuged at 16000xg for 30
minutes, and the supernatant was removed. Then, 2 m.L of 1 roM Tris (pH 7.5) was
added to the pellet. A stock solution of 4 M NaCl was added to achieve a fmal
concentration of 0.5 M by dialing down a pipette slowly while stirring for 45 minutes.
The sample was again centrifuged at 16000xg, and the supernatant was collected.

eM Sepbadex C25 Treatment. The supernatant (-5

mL) was dialyzed overnight in 1 L

borate buffer (0.6 M NaCI, 10 mM borate [pH 9.0], 50 roM PMSF) in a 10,000 MWCO
Slide-A-Lyzer cartridge (pierce). Following this treatment, 0.03 glmL of CM-sephadex
C25 was added to the dialysate, and the mixture was stirred on ice for 1 hour. The

2]

mixture was centrifuged at 11000 rpm in an Eppendorf microcentrifuge (Model 5402) for
30 minutes at 4°C. The supernatant was then brought to 2.6 M NH4 S0 4 by adding dry
ammonium sulfate over the course of30 minutes white stirring at 40 C. The solution was
then centrifuged in a Beckman L7-55 Ultracentrifuge at 100,000xg for 20 minutes at 40
C, and the supernatant (-4 rnL) was retained.
Gel Electrophoresis of the Purification. 12% SDS PAGE was run on the purified
protein as the purification was taking place, and 40 J.lL aliquots were taken following
each purification step. The gel was made using 30% acrylamide (19 acrylamide: 1
bisacrylarnide). The gels were poured in plates that were 19 cm by 16 em and 0.8 mm
wide. A ten-tooth comb was used to load the samples (each well 17 mm x 13 mm).
Samples were loaded with an equivalent amount of Laemmli Sample Buffer (BioRad)
with I}-mercaptoethanol. The gels were run in Tris-glycine buffer (5x stock: 15.1 g Tris
base, 94 g glycine, 900 mL distilled water, 50 mL 10% SDS, to a final volume of 1 L) at
40 rnA for approximately 1.75- 2 hours until the dye front reached the edge of the geL
StJlining of the Gels. Several staining techniques were attempted to stain the gel. A
summary of them is given in Table 1.
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Staining Techniques
Coomassie Blue

0.3 M CuCh

Basic Protocol
Stain with Coomassie Blue
Destain with 30% (v/v)
methanol: 10% acetic acid
(v/v) in distilled water
Stain for 5~ 7 minutes.
Wash with 3x wI dH 2O.

Bands
Dark Blue on a lighter blue
background

clear bands with light blue
/green background

KCl DTT (Hager and
Burgess 1980)

Rinse gel with ddH20, stain Clear bands, white
with cold 0.25 M KCI and 1 background
roM DTT, destain for 1 hr.
Clear bands with white
Rinse in dH20 I minute,
ZnSOJImidazole
(Fernandez-Patron et aI.
background
soak in 100 mL of 0.2 M
1995)
imidazole with 0.1 % SDS
for 15 minutes, discard
solution and immerse in SO
100 mL of 0.2 M Znso 4
Table 1. The staining techniques, basic protocol and band characteristics used for the
12%SDSPAGE.

Native Gel Electropboresis and Staining. Several different buffer systems were used
for running the native gels. A 12.5% native gel was run in each case and the buffer
systems are summarized in Table 2. In each case, the gel recipe used was 16.8 mL of
30% acrylamide/0.8% bisacrylamide, 10 mL of 4x buffer, 12.98 mL of H 20, 0.2 mL of
10% NfuS04, 0.02 mL ofTEMED. The samples were run in Ix gel loading buffer (6x:
0.25% bromophenol blue, 0.25% xylene cyanole FF, 40% (w/v) sucrose in water). The
native gels were premn for -30 minutes at 6 V and then run at 15- 30 rnA for varying

amounts of time.
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pH
Recipe
24.23 g Tris base, pH with
7.2
HCI, bring volume to I L
7.1
24.23 g Tris base, pH with
Tris
HCI, bring volume to 1 L
Glycine
15.01 g of glycine, pH with 9.7-9.8
NaOH, bring volume to I L
Glycine
15.01 g of glycine, pH with 10.2
NaOH. bring volume to 1 L
Table 2. The buffer systems used for natIve, nondenatunng electrophoresIs.

Buffer
Tris

Preparation of Domain Peptides
Transformation of Competent Cells with pT7-ffi\1GdomA and pT7-HMGdomB.
BUI (DE3)pLysS Competent E. coli cells (Novagen) were thawed on ice and mixed to
ensure that cells were evenly suspended. 20
tubes and I

~

~

of cells were pipetted into pre-chilled

ofpT7-HMGdomA plasmid (0.6 mg/mL) or 3 ilL pT7-HMGdom B (0.2

mglmL) was added directly to cells. The cells were stirred gently to mix, and tubes were
placed on ice for 5 minutes. The cells were heated for 30 sat 42° C in a water bath and
placed on ice for 2 minutes. Then, 80 ilL of room temperature SOC medium was added.
The cells were plated on LB plates containing 100 J.!g/mL of ampicillin and grown
overnight at 37°C. After 24 hours of growth, colonies were picked from both plates.
Small-scale Cultures and Induction. The induction was carried out using a modification
of the protocol of Chow et al. (1995). The picked colonies were placed in 5 mL of LB
broth with 100

~rnL

of ampicillin and grown overnight at 37°C with shaking. The next

day, the absorbance of a small amount of the culture was taken at 600 om using a
Shimadzu spectrophotometer. The absorbance was adjusted to 0.8 ODs with LB broth.
One of the cultures picked from each plate was then induced with IPTG by making the
culture 1 mM in IPTG. The other cultures were not induced.
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The cells were then

allowed to grow for an additional 2 hours and were then centrifuged for 10 minutes at
51 OOxg to pellet the cells. 1/30 volume of cell1ysis buffer (50 roM Tris [pH 7.2], 5 mM
J3-mercaptoethanol, 20 mM NaCl, 10 mM EOTA, 10 roM EDTA, 1 mM PMSF) was then
added to the cells. The cells were lysed by sonication (Fisher Sonic Dismembrator
Model 300) (2x 30 seconds) for each sample. The lysate was then cleared by
centrifugation at 16,000xg for 30 minutes at 4° C. The cells from the lysate were
resuspended, and 40 J.1L of the lysate was used to test for induction by 12% SDS PAGE.

Purification of Induced Cells. The induction protocol was then scaled up and a 25 mL
LB culture with ampicillin (lOOJ,lglmL) was made. The culture was induced with !PTG
(l mM) and allowed to grow for 2 hours following induction before the cells were

collected by centrifugation at 5100xg for 10 minutes at 4°C. 1130 volume of cell lysis
buffer was added to tbe cells, which were sonicated as described above. The lysate was
cleared by centrifugation at 16,OOOxg for 30 minutes. The supernatant was then dialyzed
overnight against buffer A (50 mM Tris [pH 7.2J, 50 roM NaCl, 5 roM

p

mercaptoethanol). Then, 0.02 g of CM sephadex C25 was added to the dialyzed
supernatant and allowed to stir for 1 hour at 4° C. The supernatant was removed and the
CM sephadex C25 was washed 3x with buffer A with centrifugation at 4° C in between
washes. The absorbance of each sample at 280 nm was also taken. Four additional
washes were done, but no significant drop-off in absorbance was seen. The CM
sephadex C25 was then washed with 0.05 M NaCl and centrifuged for 10 minutes at
6500xg. The concentration of NaCI added was then increased sequentially with each
wash from 0.1 to 0.15 to 0.2 to 0.25 M and in between each addition the CM

2S

sephadex/NaCI mixture was centrifuged at 6500xg at 4° C. 12% SDS PAGE was run on
the supernatant collected from each wash.
The purification with CM-sephadex C25 was also attempted using the lysate from
sonication, which was made 2.6 M in Nl!4S04 and 0.5 M in NaCl. The NaCl was added
slowly over 15-20 minutes, and the NH.tS04 was added slowly over 30 minutes. The
solution was then dialyzed against buffer A overnight before the addition of the CM
sephadex C25. The CM sephadex C25 was allowed to stir for 1 hour at4° C. The
mixture was then centrifuged at 4° C, the supernatant was removed., and the CM

sephadex C25 was washed 4x with buffer A and then with 0.05 M NaC!. The NaCl
concentration was increased in increments of 0.05 from 0.05 to DAD M NaCl, and 12%
SDS PAGE was carried out for the various supernatants.
Purification with DEAE Cellulose. The cells were induced, collected and lysed as
described above. They were made 0.5 M in NaCI and 2.6 M in ammonium sulfate and
then centrifuged for 5 minutes to clear the mixture. Then, DEAE cellulose (about

~

of

the volume of the lysate) was added and allowed to stir at 4°C for 1 hour. The solution
was then centrifuged at 4°C for 10 minutes and washed with buffer A four times. The
supernatant was collected following each washing, and the absorbance was taken at 280
DID.

The DEAE cellulose was then washed with NaCI in increasing concentrations from

0.05 M NaCI to 0.30 M NaCl with centrifugation (6500xg, 10 minutes, 4 0 C) and
removal ofsupematant between washings. 12% SDS PAGE was run on the purification,
and the gel was stained with Coomassie Blue. The sample was also washed with 0.3 M
NaOAc (pH 5.2) during one purification attempt and the absorbance at 280 nm was taken
to see if we protein recovery increased.
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Cation Exchange Column Chromatography. A CM sephadex C25 column was used to
purify the domain peptides. To prepare the column, 0.6 g of CM sephadex C25 was
added to -200 mL of distilled H 20 and boiled for 1 hour. It was then allowed to cool and
the H 20 was decanted. The CM-sephadex was washed with buffer A (50 mM Tris, 50

mM NaCl, 5 roM

PME [pH 7.2]) after which time most of the buffer was poured offwith

an equal volume of gel and buffer remaining. A 0.7cm x 10 cm column was fIlled about
~

fuU with buffer A. The CM sephadex C25 slurry was then added to fill the column

halfway, and the buffer was allowed to drip out until it reached the top of the slurry. The
CM sephadex C25 was added until the level of CM sephadex C25 was halfway up the
column and the gel was sufficiently packed. The column was filled with buffer A and
allowed to drain to the top of the packing material.
The HMG domain A product was purified as described above to the point of
dialysis in buffer A and then brought to 2.6 M in (NfuhS04 by adding the (NlL)2S04
slowly over 30 minutes. This mixture was then centrifuged for 10 minutes at 6500xg to
clear the precipitate. Approximately 1 mL of sample was added to the column along with
1 mL of buffer A, and 2-mL fractions were collected. The absorbance was taken of each
fraction at 280 om When the absorbance did not seem to be dropping off, the
concentration ofNaCl in the buffer was increased to 0.2 M. 12% SDS PAGE was run on
the fractions that appeared to have proteins to check the effectiveness of the purification
process.
Anion Exchange Chromatography of HMG Domain B. A DEAE cellulose column
was prepared by first boiling -0.5 g of DEAE cellulose in -300 rnL of H 20 for one hour.
The DEAE cellulose was equilibrated with buffer A by washing twice with buffer A. A
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column (1.0 em x 20 em) was filled

~

full with buffer A, and DEAE cellulose was added

to fill the column 1/3 of the way full. Buffer A was allowed to flow through until the
DEAE cellulose had completely settled. 1 mL of the HMG domain B peptide, which was
prepared by making it 2.6 M in CNfuhS04 and centrifuging as described above, was
added along with I rnL of Buffer A, and this was drained to the top of the DEAE
cellulose before the column was filled with buffer. 2-mL fractions were collected until
the absorbance appeared to level off (A 280 .....().1). Then, the buffer was made 0.2 M in
NaCI and then 0.4 M in NaCI while fractions were continuously collected and the A 280
was monitored using the Shimadzu spectrophotometer. Again, 12% SDS PAGE was run
on the fractions collected.
Gel Filtration of Cation Exchange-purified Protein. The product resulting from the
cation exchange column chromatography was further purified by gel filtration. A gel
filtration column was run using Sephadex G-75. The column was prepared by starting
with -2 g of dry sephadex G-75 and swelling it in -200 mL of H 20 by boiling for 1 hour.
The gel was then equilibrated with column buffer A by decanting the H 20 and replacing
it with -100 mL buffer A twice. A column (30 em x 1 em) was filled to within 1 inch of
the top with sephadex 0-75 and allowed to settle. Buffer A was run through the column,
and the fraction with the highest absorbance from the cation exchange column was
applied to the column (HMG domain A peptide) and allowed to drain to the top of the gel
before more buffer was added. 2-mL fractions were collected, and once again 12% SDS
PAGE was run to check the efficacy of the purification process.
Binding Assays
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Purification of the Oligomers. The original oligomer used had the following sequence
(5'-CAT TGA CAA GGG ACC CAA GAC TTC CGA CGG TA-3') (32-bp) (Integrated
DNA Technologies). Denaturing PAGE oftbis DNA and its complementary strand was
run on a gel (25.2 g urea, 30 rnL 40% acrylamide, 6 mL 10 X TBE, 300

~L

20% APS, 40

}lL TEMED) that was 19 em x 16 em using 1.5 mm spacers in a one-well comb. The gel
was allowed to polymerize for 1 hour before being pre-run for 1 hour at 400 V. Equal

amounts of loading dye (5 M urea/O.OI % xylene cyanole) and DNA (-20 J.LL of each)
were loaded after heating at 37 0 C. The gel was run for 3 hours at 400 V and the desired
band of DNA was excised for gel purification. The band was crushed, placed into a test
tube with elution buffer (50 mL SDS, 19.7 g NHtOac, 1.073 g MgOAc, dH 20 to 500 mL)
and set to shake vigorously overnight at 37 0 C. It was then centrifuged to pellet the gel
(2000 rpm, 3 minutes). The supernatant was collectecL and another pipette full of elution

buffer was added to the test tubes with the gels. The tubes were allowed to shake for an
additional hour at 37 0 C and were centrifuged at 3000 rpm in an Eppendorf
microcentrifuge (Model 5402) for 3 minutes. This was repeated once more, and the
supernatants were pooled.
The samples were then run through a Sep Pak. C-18 cartridge. The cartridge was
attached to a 5-mL syringe and activated by washing with 100% acetonitrile and then

with water. The DNA was loaded and then washed with 10 roM NH 4 0ac before the
DNA was eluted with 25% acetonitrile/water solution. The DNA was then lyophilized.
Each sample was dissolved in TE buffer, tubes were collected, and the absorbance at 260
nm was taken.
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32P-labeliog of the DNA. 0.5 OD's of purified single-stranded DNA was heated at 37 0 C
for 10 minutes. It was then labeled in T4 polynucleotide kinase (PNK) buffer (NEB)
using 2

.uL ofy-ATP and 1 JlL ofT4 polynucleotide kinase in a 20-JlL reaction.

This

reaction was incubated at 37 0 C for 30 minutes. The labeled DNA was then ethanol
precipitated by adding 1/1 0 volume of 3M NaOAc, vortexing and adding at least 2
volumes of EtOH. The DNA was chilled for 20 minutes at -20 °C and centrifuged at
12,000 rpm in an Eppendorfmicrocentrifuge (Model 5402) for 10 minutes at 4 0 C. The
supernatant was removed, an excess of 80% ethanol was then added to the pellet, and the
DNA was again chilled and centrifuged at 12000 rpm for 10 minutes at 4 0 C. The
precipitation was monitored using a Geiger-Muller counter to ensure that the labeled
DNA was retained. The DNA was then lyophilized, and 0.6 ODs of the complementary
strand was annealed by heating with the labeled DNA strand in 98

JlL of Tris-EDTA (TE

) buffer for 10 minutes at 70 0c. The DNA was then cooled to allow for the annealing.
The DNA was cross-linked with 2 JlL DEB (250 mM DEB) and allowed to incubate for 1
hour at 37

0c.

This DNA was then ethanol precipitated as described above and

lyophilized. Some of the DNA was not treated with DEB to serve as a control for the
binding assays. The labeled DNA was then dissolved in 100 ilL of H 20.
Alternative Purification of DNA. A second oligomer was also used for the binding
assays with the following sequence (5' -CTA AGT CTA TGG TCC TAC GTC GTT TAT
CAT- 3') (30 bp) (Integrated DNA Technologies). This DNA was first 5,-32P-labeled
and then annealed with its complement and cross-linked. The cross-linked DNA was
then purified by denaturing PAGE (gel recipe: 19 g solid acrylamide, 1 g bisacrylamide,
49.5 g solid urea stirred with 10 mL of lOx TBE and 20 mL of distilled water brought to
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100 mL and filtered for a gel that is 41 em x 37 em x 0.35 em). The gel was prerun at 60
W for 2 hours. The cross-linked, dried DNA was then dissolved in 10 j.1L of 5 M
urea/O.Ot % xylene cyanole dye and loaded into the wells of the gel. The gel was
electrophoresed at 60 W for -2 hours. The gel was then exposed to X-ray film and was
developed the next day. The low-mobility bands representing cross-linked DNA were
identified and cut out The DNA was eluted from the bands by crushing the gel pieces
and soaking them in elution buffer while vortexing for 2 hours. The gel pieces were
centrifuged (3 minutes, 12000 rpm), and the supernatant was removed. A second elution
with elution buffer was done for -1.5 hours, and the gel pieces were centrifuged as
before. The eluant was run through a Sep Pak C-18 cartridge as described above, and the
DNA was lyophilized. This purification following cross-linking was done in place of the
purification before cross-linking in an effort to isolate the DNA that had been cross
linked from the majority of DNA, which was not cross-linked. The DNA was then
renatured by heating at 65

0c.

Preparation of Self-complementary Strand. A self-complementary strand with the
following sequence (5'-TATATGGGCCCATATA-3') (16 bp) (Integrated DNA
Technologies) was 5'-radiolabe1ed with 32 p and ethanol precipitated as described above.
The DNA was lyophilized and allowed to anneal with itself by heating to 60° C. The
labeled DNA was then treated with DEB (250 mM) and incubated at 37 0 C for one hour.
The cross-linked DNA was ethanol precipitated as described and lyophilized.
Binding Assays.. The binding assays were carried out using an adaptation of the protocol
of Dunham and Lippard (1997). I j.1L of DNA was use for the binding study (-1000 cpm)
and titrated with varying amounts of the HMG domain A proteins. The concentration of
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the protein was determined from the

A280

(extinction coefficient 14,000 M- 1cm- 1

(Dunham & Lippard, 1997», and the concentration of the DNA was estimated prior to
radiolabeling from the 00 of 1 ~ dissolved in 1 mL of solvent (in this case about
10,000 nM). The highest concentration of protein used (10,000 oM) was roughly equal
to that of the DNA and the ratio of protein: DNA was decreased by an order of magnitude

in each reaction yielding the following ratios: 1: 10, 1: 100, 1: 1000, 1: 10,000. A control
was run with no protein, and a second control containing the labeled single-stranded
oligomer was also used. The DNA, protein and 1 ilL of lOx reaction buffer II (10 mM
HEPES, to pH 7.5,100 roM MgCh, 500 roM Liel, 1 M NaCI, 10 roM spennidine, 2

°

mglmL BSA, 0.5% Igepal) were incubated in a fmal volume of 1 IlL on ice for one
hour. A set of control reactions was also prepared in the same way using the non-cross
linked DNA. The DNA was run in a 6% native gel (24 mL water, 8 mL 30% acrylamide,
4 mL 5x TBE, 4 mL 50% glycerol, 0.4 mL 20% APS, 16 JlL TEMED for a 19 cm x 16
crn x 0.8 rom gel). The gel was premn in a cold room at 200-250 V while the DNA was
incubating. Following this, reaction mixture was loaded with 6x native dye (0.05%
xylene cyanole in 50% glycerol). The gel was run for approximately 2 hours (until the
dye front moved -1/2 way down the gel). The gel was then dried on a gel drier (Hoefer
Scientific Drygel Sr. slab gel dryer Model SE 1160), and the bands were visualized using
a phosphorimager (BioRad) and the Molecular Analyst software.
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Results
Purification ofHMGl from chicken blood by salt extraction. The HMGl protein was
obtained from chicken erythrocytes by lysing the nuclei and using NaCI salt extraction.
Low molecular weight impurities were reduced by dialysis, and the protein was further
purified by treating with eM Sephadex C25 medium. The results of the purification can
be seen in Fi

4.
3

2

4

Figure 4. 12% SDS PAGE of the proteins purified from the chicken erythrocytes.
HMG 1 and HMG2 are both indicated and, as shown, have similar mobilities.
Lane 1 contains the supernatant after dialysis against borate solution, lane 2
contains the product of HMG CM Sephadex C25 mixture with the CM Sephadex
present and lane 3 shows the supernatant after the CM Sephadex C25 was
removed. Lane 4 contains the protein after it was dialyzed with Buffer A.

The SDS PAGE indicated that the protein bad not been completely purified from
the other cellular proteins. The rough purification seemed to be fairly successful
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however, and past attempts to purify the protein by further column chromatography were
unsuccessful as the protein remained stuck on the column (Frazar, 200t).

Staining of HMGl. The staining procedures used are listed in Table 2 as explained
previously. These procedures were used in an attempt to allow native gel purification of
HMG t from HMG2. Unfortunately, native gel purification cannot be achieved upon
Coomassie Blue staining due to its irreversible modification of the protein. While
Cooroassie Blue staining was quite successful, other staining techniques such as copper
staining, zinc-imidazole staining, and potassium staining were unsuccessful in staining
the protein. No bands were visible in the gels stained with these alternative techniques.
We therefore pursued purification of domain proteins from E. coli.
Transformation and Induction of E. Coli. The transformation of E. coli resulted in the
successful growth of several colonies on ampicillinlLB agar plates. This suggests that the
E. coli took up the plasmid containing the HMG domain sequences. The SDS PAGE of

the induction also shows that the E. Coli were induced to express the inserted domain
peptides. The gel is shown in Figure 5.
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Figure 5. 12% SDS of the results ofioduction with IPIG. Lane 1 contains
induced HMG domain A peptide. Lane 2 contains uninduced HMG domain A peptide.
Lane 3 contains induced HMG domain B peptide. Lane 4 contains uninduced HMG
domain Betide. The molecular wei t standard is shown 00 the ri t.

Purification of HMG Domain Peptides by Chromatography. Several different types
of chromatography were used to purify the proteins. The ftrst used was cation exchange
chromatography. Both initial washing with CM Sephadex C25 and more traditional
column chromatography with CM Sephadex C25 were attempted. Washings with CM
Sephadex C25 were somewhat helpful in purifying the protein but did not remove all of
the impurities. DEAE cellulose anion exchange chromatography also only marginally
purified the protein. Overall, the use of chromatography was not extremely effective.
Using a combination of ion exchange chromatography and gel filtration chromatography,
we saw a slight improvement in the purity of the protein samp les. Therefore, this protein
was used for the binding assays.
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wa~

g I purified (Figure 6).

We also see that purification of the cross-linked DNA followed by heating at 65° C
followed by slow cooling appears to destroy the cross-link and result in more singlestranded product appearing (Figure 7).

os ONA -":-----.,
5S DNA --'-~"d~~iI

Figure 7. 6% Native Page of heat-treated DEB cross-linked 30-bp DNA and interactions
with HMG domain A. It appears that most of the duplex DNA was in fact lost in this
process. Lane I contains the labeled oligomer. Lane 2 contains a 1: I ratio of protein to
DNA. Lane 3 contains a 1:10 ratio of protein to DNA. Lane 4 contains a 1:100 ratio of
protein to DNA. Lane 5 contains a 1: 1000 ratio of protein to DNA. Lane 6 contains
single-stranded, labeled DNA.

Binding Assays. The binding assays done with globally modified 30-bp DNA showed
that, at the highest concentration of HMG domain A, the protein seems to bind to the
DNA and form a complex that results in a low mobility band in the gel visible upon
overexposure. The native gel of the DEB-cross-linked DNA and the DNA that was not
cross-linked with DEB is shown in Figure 8. No low mobility band was seen in the lanes
containing smaller amounts of protein, and even upon overexposure no low mobility
bands appeared in the control gel. No bands were visible when a similar assay was done
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with 32-bp DNA, and the results of binding assays done with the self-complementary 16
mer have been inclusive thus far (data not shown).

Figure 8. 6% Native gel binding assays. The gel containing 30-bp DEB-cross
linked DNA is shown in A and B with B showing the overexposure of A. The native gel
containing control DNA that has not been cross-linked is shown in C and D with D
showing the overexposure of C. For each of the gels, lane 1 contains no protein. Lane 2
contains a 1:1 ratio of domain A to DNA. Lane 3 contains a 1: 10 ratio of protein to
DNA. Lane 4 contains a l: 100 ratio of protein to DNA, and lane 5 contains a I: 1000
protein to DNA ratio. Lane 6 contains the single-stranded DNA.
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Discussion
After attempting several purification and staining protocols, we succeeded in
partial purification ofHMGl. NaCl extraction followed by dialysis removed many of the
low molecular weight impurities, and CM Sephadex C25 treatment allowed HMG 1 to
remain in the supernatant while other positively charged impurities were captured by the
resin. 12% SDS PAGE (Figure 4) shows that following purification with CM Sephadex
C25, the extract was relatively enriched in HMG1 and HMG2 and contained lesser
amounts of other proteins isolated from the chicken erythrocytes. We had hoped to
isolate HMG1 from HMG2. This was a major obstacle given their similar molecular
weights and charge characteristics. We initially hoped to find an appropriate staining
protocol that would allow us to reversibly stain the 12% SDS PAGE gels and excise the
HMGl band from the gel to perform gel extraction of the HMGl protein without having

to use column chromatography or HPLC. Unfortunately, all reversible staining
techniques attempted with SDS PAGE and with non-denaturing native gels were
unsuccessful. Coomassie blue staining was successful, but the use of this dye results in
permanent staining and does not allow for the renaturation that is possible when
reversible staining and native gel electrophoresis techniques are combined.
Given that the DNA-binding domains of HMG 1 are the HMG A domain and the
HMG B domain, it seemed reasonable to turn our attention from the complete HMGl
protein to these domains. We hoped to learn more about their ability to bind modified
DNA but first needed to express, isolate and purify them from E. coli. Tills purification
also proved to be more challenging than anticipated. We initially attempted to purify the
domain peptides in the same manner as we purified the HMG 1 protein using eM
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Sepbadex C25 treatments to bind the protein and then wash away many of the impurities.
While this technique was somewhat effective, the SDS PAGE clearly shows that
impurities were still found in the protein extract. Further, two bands appear in the gel
showing the results of induction by IPTG (Figure 5). This suggests that the peptide may
be breaking down during electrophoresis. It is also possible that our protein is dimerizing
although it is difficult to determine exactly which of these events occurred from the
molecular weight standard.

In addition to the crude purification attempted, we used column chromatography
with CM Sephadex C25 followed by gel filtration and also DEAE cellulose anion
exchange chromatography. The HMG domain proteins at cationic around pH 7 and
should therefore stick to the CM Sephadex C25 column. A salt gradient could then be
use to elute them (Chow et ai, 1995). However, the proteins did not stick to the column.
Therefore, purification was attempted using a DEAE column. We hoped that the protein
would stick to the column or that impurities would stick to the column and our protein
would flow through if it was positively charged.. In fact, the protein did not stick to the
DEAE column and was simply washed through and collected in the first few fractions
after the void volume. Few impurities were removed using this technique. Gel filtration
was attempted following CM Sephadex treatment in an attempt to separate our mixture of
proteins by size and get a reasonably pure sample of each of the domains. Running a CM
Sephadex C25 column first, and then running the gel filtration column seemed to increase
the purity of the protein, but both low molecular weight and high molecular weight
impurities remained as seen in Figure 5. Published protocols, including that of Chow et
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al. (1995), suggest that LC may be efficiently used to purify both HMG domain A and
HMG domain B with a cation exchange S sepharose column.
After many unsuccessful attempts at completely isolating the HMG domain
peptides, we decided to proceed with the binding studies. While attempts were made
previously to do such binding studies with the complete HMG 1 protein, we decided to
focus our efforts on the domain peptides. These peptides offered many advantages.
Initially, we believed that these would be more easily purified and at the very least allow
us to do the binding studies without worrying about competition between HMG 1 and
HMG2. The domain peptides are probably also less toxic to E. coli and therefore were
more easily expressed via plasrnids than the entire HMGl protein (Frazar, 2001). The
presence of the carboxy terminal tail in vitro lowers the affinity of the HMG boxes for
most DNA substrates (Sheflin et al., 1993; Lee & Thomas, 2000). Therefore, working
with the domains without the tail may improve our ability to see interactions between the
DNA and the protein. Finally, the use of the domain peptide allows for the use of smaller
oligomers in the binding study. Studies with the HMG 1 protein all used duplexes of at
least 100 bp, which are more difficult to renature following purification of cross-link.
Assays using the A and B domain of HMG 1 could be attempted with shorter oligomers
that can be cross-linked and renatured without causing strand scission or inducing other
changes in the DNA that might affect subsequent interactions with the domain peptides.
Millard and Wilkes (2001) work with DEB had previously shown that DEB cross-links
are quite heat sensitive and therefore suggest that purification of these DNA containing
such cross-links could be an important consideration for our work.
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The labeling and isolation of the DNA appeared to go quite smoothly. By using
standard 5'-radiolabeling with 32p it was possible to label the DNA in a predictable
manner and monitor the process using a Geiger-Muller counter. Reaction conditions
were such that each duplex would on average contain only one alkylation event (Millard
& Wilkes, 2001). Interstrand cross-links between guanines could be purified from other

products (including intrastrand cross-links) that might have formed. Purification of the
cross-linked DNA showed us that a large amount of the DNA that was treated with DEB
was not cross-linked (Figure 6). This agreed with the previous results, which indicated
that we should expect only 10-15% of the duplex DNA to be cross-linked by treannent
with DEB. Excision of the interstrand cross-linked bands from the gel and elution from
the gel bands resulted in further loss of DNA. Some of the DNA remained in the gel as
seen by checking the radioactivity of the gel following elution and removal of the eluant.
This loss is expected and seemingly unavoidable. Purification of the oligomers in this
manner also results in denaturation of the double strand. The two complementary strands
remain cross-linked by the DEB but must be renatured. Unfortunately, this renaturation
process appears to be destructive to the DNA. Figure 7 suggests that strand scission may
be a major concern in purification of the cross-links. DEB cross-links are not stable at
the temperatures needed to re-anneal the oligomer of 30 nuc1eotides. Therefore,
purification in a urea denaturing gel does not seem to be the ideal situation if the
conditions necessary for renaturation (temperatures above -37 0 C) are harmful to the
cross-links. Millard & Wilkes (2001) obtained similar results concerning renaturation of
the cross-links. Since the DEB cross-links are heat sensitive, it seemed that using a
smaller oligomer might be helpful. This would result in a lower melting (annealing)
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temperature for the DNA and mean that renaturation may be carried out without
destroying the cross-links.
Some initial binding assays were done without the purification of the DEB-cross
linked DNA. The most promising result using the oligomer of approximately 30 base
pair showed that a faint low mobility band appears for the DEB-treated DNA when the
protein-to-DNA ratio is highest (Figure 8). The band most likely represents DNA that
has interacted with the HMG domain protein and therefore is not able to move through
the gel as quickly. Attempts to recreate these results with purified cross-link were
unsuccessful due to the tendency of the cross-links in the purified DNA to be destroyed
by the renaturation process. The control gel (Figure 8), whicb contained the oligomer
without cross-links. did not show a similar low mobility band providing further evidence
that HMG 1 domain A does preferentially bind to cross-linked DNA.
Another interesting result was that the HMG domain A peptide seemed to bind
the DEB-crass-linked DNA, but the HMG domain B did not (data not shown). This
could have been due to changes incurred during purification of the peptide or unknown
problems with the initial study done using HMG domain B. The A domain is known to
have a higher affinity for distorted DNA structures (Teo et al., 1999) than the B domain,
and this may be partly responsible for the lack of binding seen with the HMG B domain.
Further Study
Much work remains on this current project Ideally, the HMG 1 protein and HMG
domain peptides will be purified. This may be possible using cation exchange via HPLC
(Christine S. Chow, personal communication). This would allow us to be more confident
that the interactions we see between protein and DNA are really occurring with HM:G 1 or
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the HMG domains and not with proteins from the E. coli (in the case of the domain
peptides) or with other proteins collected from the chicken blood (in the case of HMG1).
Such purification may be particularly critical for the HMG 1 isolated from chicken
erythrocyte nuclei. It is quite likely that many of the proteins extracted from the nuclei
along with the HMG 1 may also be DNA-binding and could affect the results of our study.
Once the proteins are isolated and purified, more work could be done on the
binding studies. Binding studies done with the HMG 1 proteins will require longer
oligomers (> 100 bp). However, obtaining pure cross-link that can be renatured to
prevent destruction of the cross-links will be a chaUenge. Longer oligomers tend to have
higher melting temperatures, and DEB cross-links are heat-sensitive. If purification
could be done without harming the duplex, perhaps using HPLC or SE HPLC, the
resulting product may be more useful for this project.
For the domain proteins, further work could be done using the HMG A domain to
determine the optimal

protein-to~DNA ratio

and also to detennine to what extent HMG

domain peptides bind preferentially to cross-linked DNA rather than to non-cross-linked
DNA. It may also be useful to run a control experiment with cisplatin to be sure that the
proteins haven't been denatured in some unexpected manner. Ultimately, we might be
able to design drugs whose lesions bind tightly to the HMG proteins, which aid in eluding
repair and thus trigger the death of tumor cells.
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Conclusions
Overall, our study resulted in partial purification of the HMG I protein and of the HMG A
and B domains. In addition, we were able to carry out preliminary binding studies using
radiolabeled DEB cross-linked DNA to detennine whether HMG 1 preferentially binds to
the modified DNA. It does appear that HMG 1 binds to the modified DNA although this
interaction may be weak and that a similar interaction is not seen between HMG 1 and
DNA that bas not been cross-linked. Further studies will have to be done to determine
the optimum protein-to-DNA ratio and learn more about the interaction between HMG 1
and cross-linked DNA.
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